Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors

References

• Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev. 2017;276:5–8. doi:10.1111/imr.12531.
   PubMed Web of Science ®Google Scholar
• Tirapu I, Huarte E, Guiducci C, et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res. 2006;66:2442. doi:10.1158/0008-5472.CAN-05-1681.
   PubMed Web of Science ®Google Scholar
• Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, Choueiri TK, Bermas BL. Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum. 2018;47:907–910. doi:10.1016/j.semarthrit.2017.10.018.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–1768. doi:10.1200/JCO.2017.77.6385.
   PubMed Web of Science ®Google Scholar
• Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2018;256:187–191. doi:10.1007/s00417-017-3835-2.
   PubMed Web of Science ®Google Scholar
• Bomze D, Meirson T, Hasan Ali O, Goldman A, Flatz L, Habot-Wilner Z. Ocular adverse events induced by immune checkpoint inhibitors: a comprehensive pharmacovigilance analysis. Ocul Immunol Inflamm. 2020;1–7. doi:10.1080/09273948.2020.1773867.
   PubMed Web of Science ®Google Scholar
• Cunningham ET, Moorthy RS, Zierhut M. Immune checkpoint inhibitor-induced uveitis. Ocul Immunol Inflamm. 2020;28:847–849. doi:10.1080/09273948.2020.1801286.
   PubMed Web of Science ®Google Scholar
• Deitch-Harel I, Raskin E, Habot-Wilner Z, Friling R, Amer R, Kramer M. Uveitis induced by biological agents used in cancer therapy. Ocul Immunol Inflamm. 2020;1–5. doi:10.1080/09273948.2020.1760310.
   Web of Science ®Google Scholar
• Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. British J Ophthalmol. 2020; bjophthalmol-2020-316970.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–819. doi:10.1056/NEJMoa1002011.
   PubMed Web of Science ®Google Scholar
• Khunger A, Khunger M, Velcheti V. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis. 2018;12:1753466618767611. doi:10.1177/1753466618767611.
   Web of Science ®Google Scholar
• Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4:e000491. doi:10.1136/esmoopen-2019-000491.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services CfDCaP. Common terminology criteria for adverse events (CTCAE). 2017.
   Google Scholar
• Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California epidemiology of uveitis study. Ophthalmology. 2004;111:491–500. doi:10.1016/j.ophtha.2003.06.014.
   PubMed Web of Science ®Google Scholar
• Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45:1–13. doi:10.1097/01.iio.0000155938.83083.94.
   PubMedGoogle Scholar
• Rathinam SR, Namperumalsamy P. Global variation and pattern changes in epidemiology of uveitis. Indian J Ophthalmol. 2007;55:173–183. doi:10.4103/0301-4738.31936.
   PubMedGoogle Scholar
• Llorenc V, Mesquida M, Sainz De La Maza M, et al. Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization. Acta Ophthalmol (Oxf). 2015;93:561–567. doi:10.1111/aos.12675.
   PubMed Web of Science ®Google Scholar
• Suttorp Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844–8. Issn: 0007–1161. doi:10.1136/bjo.80.9.844.
   PubMed Web of Science ®Google Scholar
• Krumpaszky HG, Klauß V. Erblindungsursachen in Bayern–Auswertung einer repräsentativen Stichprobe der Blindengeldakten aus Oberbayern. Klin Monbl Augenheilkd. 1992;200:142–146. doi:10.1055/s-2008-1045729.
   PubMed Web of Science ®Google Scholar
• Whist E, Symes RJ, Chang JH, et al. Uveitis caused by treatment for malignant melanoma: a case series. Retinal Cases Brief Rep. 2019. doi:10.1097/ICB.0000000000000876.
   PubMedGoogle Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:306. doi:10.1186/s40425-019-0805-8.
   PubMed Web of Science ®Google Scholar
• Palmares J, Coutinho MF, Castro Correia J. Uveitis in northern Portugal. Curr Eye Res. 1990;9 Suppl:31–34. doi:10.3109/02713689008999416.
   PubMed Web of Science ®Google Scholar
• Jakob E, Reuland MS, Mackensen F, et al. Uveitis subtypes in a German interdisciplinary uveitis center—analysis of 1916 patients. J Rheumatol. 2009;36:127–136. doi:10.3899/jrheum.080102.
   PubMed Web of Science ®Google Scholar
• Ilieva KM, Correa I, Josephs DH, et al. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther. 2014;13:2769. doi:10.1158/1535-7163.MCT-14-0290.
   PubMed Web of Science ®Google Scholar
• Stjepanovic N, Velazquez-Martin JP, Bedard PL. Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol. 2016;27:998–1005. doi:10.1093/annonc/mdw100.
   PubMed Web of Science ®Google Scholar
• Yue P, Harper T, Bacot SM, et al. BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways. Oncoimmunology. 2018;8:e1512456–e. doi:10.1080/2162402X.2018.1512456.
   PubMed Web of Science ®Google Scholar
• Sarny S, Neumayer M, Kofler J, El-Shabrawi Y. Ocular toxicity due to trametinib and dabrafenib. BMC Ophthalmol. 2017;17:146. doi:10.1186/s12886-017-0541-0.
   PubMed Web of Science ®Google Scholar
• Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular adverse events associated with MEK inhibitors. Retina. 2019;39:1435–1450. doi:10.1097/IAE.0000000000002451.
   PubMed Web of Science ®Google Scholar
• Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011;2:684–694. doi:10.18632/oncotarget.323.
   PubMed Web of Science ®Google Scholar
• Kato Y, Yamamoto Y, Tabuchi H, Fukushima A. Retinal pigment epithelium folds as a diagnostic finding of Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol. 2013;57:90–94. doi:10.1007/s10384-012-0212-x.
   PubMed Web of Science ®Google Scholar
• Mihailovic N, Dyballa J, Herz S, et al. Vogt-Koyanagi-Harada-artige uveitis unter immun-checkpoint-inhibitor-therapie beim metastasierten malignen melanom. Der Ophthalmologe. 2020;117:467–471. doi:10.1007/s00347-019-00963-z.
   PubMedGoogle Scholar
• Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016;4:8. doi:10.1186/s40425-016-0114-4.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532. doi:10.1056/NEJMoa1503093.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. Jama. 2016;315:1600–1609. doi:10.1001/jama.2016.4059.
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053. doi:10.1200/JCO.2005.06.205.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030. doi:10.1200/JCO.2013.53.0105.
   PubMed Web of Science ®Google Scholar